Neurogene Inc. (NASDAQ:NGNE - Get Free Report)'s stock price hit a new 52-week high during mid-day trading on Monday . The stock traded as high as $58.00 and last traded at $57.99, with a volume of 23848 shares changing hands. The stock had previously closed at $46.07.
Analyst Ratings Changes
Separately, HC Wainwright reduced their price objective on Neurogene from $51.00 to $49.00 and set a "buy" rating on the stock in a research report on Monday, August 12th. Eight investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Neurogene currently has a consensus rating of "Buy" and a consensus target price of $51.00.
Check Out Our Latest Stock Report on Neurogene
Neurogene Price Performance
The company has a 50 day moving average of $43.68 and a 200 day moving average of $38.75.
Neurogene (NASDAQ:NGNE - Get Free Report) last announced its quarterly earnings results on Friday, August 9th. The company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($1.02) by ($0.07). The business had revenue of $0.93 million during the quarter. Equities analysts predict that Neurogene Inc. will post -4.47 EPS for the current fiscal year.
Institutional Investors Weigh In On Neurogene
Several institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. boosted its holdings in Neurogene by 906.5% in the first quarter. Vanguard Group Inc. now owns 507,483 shares of the company's stock valued at $25,831,000 after purchasing an additional 457,062 shares during the last quarter. Baker BROS. Advisors LP raised its position in shares of Neurogene by 0.6% during the 1st quarter. Baker BROS. Advisors LP now owns 456,015 shares of the company's stock worth $23,211,000 after purchasing an additional 2,499 shares during the period. Driehaus Capital Management LLC increased its position in Neurogene by 123.8% in the 2nd quarter. Driehaus Capital Management LLC now owns 102,187 shares of the company's stock valued at $3,719,000 after acquiring an additional 56,533 shares during the period. Integral Health Asset Management LLC acquired a new stake in Neurogene in the 2nd quarter valued at approximately $2,547,000. Finally, Marshall Wace LLP increased its position in Neurogene by 37.2% in the 2nd quarter. Marshall Wace LLP now owns 41,447 shares of the company's stock valued at $1,508,000 after acquiring an additional 11,229 shares during the period. Hedge funds and other institutional investors own 52.37% of the company's stock.
Neurogene Company Profile
(
Get Free Report)
Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.
Further Reading
Before you consider Neurogene, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neurogene wasn't on the list.
While Neurogene currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
